Reviews
Candidate autoantibodies for primary Sjögren's syndrome: where are they now?
J. He1, J. Jiang2, K. Baumgart3
- Department of Rheumatology, Concord Repatriation General Hospital, Sydney, and Department of Immunology, Douglass Hanly Moir Pathology, Sonic Health, Macquarie Park, Australia. jingyajianna.he@health.nsw.gov.au
- Department of Immunology, Blacktown Hospital; School of Medicine, University of Sydney; and Blacktown Clinical School, School of Medicine, Western Sydney University, Australia.
- Department of Immunology, Douglass Hanly Moir, Pathology, Sonic Health, Macquarie Park, Australia.
CER15394
2022 Vol.40, N°12
PI 2387, PF 2394
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 35616578 [PubMed]
Received: 07/12/2021
Accepted : 14/02/2022
In Press: 26/05/2022
Published: 20/12/2022
Abstract
Although ANA, SSA and SSB antibody testing are universally accepted biomarkers for Sjögren’s syndrome (SS) diagnosis, they do not occur in all patients. Up to 18% of SS patients are seronegative, with potential for delayed or missed diagnosis. There are no clinically available autoantibodies with predictive value for SS end-organ complications. Over the last three decades, novel autoantibodies for SS diagnosis and monitoring have been identified but few have transitioned from research studies to clinical use. We performed a literature review of candidate serum autoantibodies to examine their persistence in the literature and potential clinical utility. Of the nineteen autoantibodies we identified, AQP5, SP-1, CA6, and PSP Abs have the most promise. Larger cohort studies are needed to determine their potential contribution in SS management.
